Pulmonary Malignant Peripheral Nerve Sheath Tumor in a Patient With Rheumatoid Arthritis-Associated Interstitial Pneumonia [0.03%]
合并类风湿性关节炎相关间质性肺炎患者发生肺恶性外周神经鞘瘤一例
Keigo Koda,Mikio Toyoshima,Atsuki Fukada et al.
Keigo Koda et al.
Elodie Negre,Amandine Coffy,Alexandra Langlais et al.
Elodie Negre et al.
Introduction: This study aimed at generating a new simplified prognostic score (SPS) using common clinical and biological variables to discriminate a limited number of subgroups of patients with SCLC differing by their ov...
Sai-Hong Ignatius Ou,Viola W Zhu,Misako Nagasaka
Sai-Hong Ignatius Ou
Since the discovery of anaplastic lymphoma kinase fusion-positive (ALK+) NSCLC in 2007, the methods to detect ALK+ NSCLC have evolved and expanded from fluorescence in situ hybridization and immunohistochemistry to next-generation DNA seque...
Alex A Adjei
Alex A Adjei
Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center [0.03%]
靶向测序在肺癌临床应用中的效用：来自瑞典一个自治保健中心的体验
Sofi Isaksson,Bassam Hazem,Mats Jönsson et al.
Sofi Isaksson et al.
Objectives: Mutation analysis by massive parallel sequencing (MPS) is routinely performed in the clinical management of lung cancer in Sweden. We describe the clinical and mutational profiles of lung cancer patients subje...
Ryo Toyozawa,Naoki Haratake,Gouji Toyokawa et al.
Ryo Toyozawa et al.
Introduction: During treatment with immune checkpoint inhibitors, immune-related adverse events sometimes occur, and their management is a critical concern associated with such treatment. Encephalitis and meningitis are s...
Alicia Quilez,Edgar F Guillen,Luisa Sánchez et al.
Alicia Quilez et al.
The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy [0.03%]
程序性死亡蛋白1抑制剂的较长半衰期可能会在后续EGFR酪氨酸激酶抑制剂治疗后增加免疫相关不良事件的发生频率
Yuki Shinno,Yasushi Goto,Mayu Ohuchi et al.
Yuki Shinno et al.
Introduction: EGFR tyrosine kinase inhibitors are one of the key drugs for treatment of NSCLC with EGFR mutations. In recent times, immune check-point inhibitors (ICIs) have also been widely used for patients with NSCLC. ...
Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study [0.03%]
具有BRAF突变的非小细胞肺癌患者可能不会从免疫检查点抑制剂中获益：基于人群的研究
Chenxing Zhang,Chenyue Zhang,Jiamao Lin et al.
Chenxing Zhang et al.
Introduction: There is no consensus on whether immune checkpoint inhibitors (ICIs) would offer comparable benefit in mutant-BRAF NSCLC. We, therefore, conducted a study to ascertain the role of ICIs in mutant-BRAF NSCLC. ...
Veterans Affairs Insurance Disparities for Metastatic Lung Cancer in the Hawaiian Islands [0.03%]
夏威夷群岛退伍军人肺癌转移的医疗保险差异问题
John Q Lin,Shirley Q Li,Todd A Pezzi et al.
John Q Lin et al.
Introduction: The highest concentration of military personnel in the United States is located in Hawaii where occupational exposures, such as to asbestos in the Pacific Fleet shipyards, predispose them to thoracic maligna...